Methods and Devices for Cryopreservation of Biological Cells and Tissues by Gao, Dayong et al.
University of Kentucky
UKnowledge
Mechanical Engineering Faculty Patents Mechanical Engineering
10-20-2009
Methods and Devices for Cryopreservation of
Biological Cells and Tissues
Dayong Gao
University of Kentucky
Gary Van Zant
University of Kentucky, gvzant1@uky.edu
XiangDong Cui
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/me_patents
Part of the Mechanical Engineering Commons
This Patent is brought to you for free and open access by the Mechanical Engineering at UKnowledge. It has been accepted for inclusion in Mechanical
Engineering Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Recommended Citation
Gao, Dayong; Van Zant, Gary; and Cui, XiangDong, "Methods and Devices for Cryopreservation of Biological Cells and Tissues"
(2009). Mechanical Engineering Faculty Patents. 5.
https://uknowledge.uky.edu/me_patents/5
(12) United States Patent 
Gao et a]. 
US007604930B1 
US 7,604,930 B1 
Oct. 20, 2009 
(10) Patent N0.: 
(45) Date of Patent: 
(54) 
(75) 
(73) 
(*) 
(21) 
(22) 
(63) 
(60) 
(51) 
(52) 
(58) 
METHODS AND DEVICES FOR 
CRYOPRESERVATION OF BIOLOGICAL 
CELLS AND TISSUES 
Inventors: Dayong Gao, Lexington, KY (US); 
Gary Van Zant, Lexington, KY (U S); 
XiangDong Cui, Lexington, KY (U S) 
Assignee: University of Kentucky Research 
Foundation, Lexington, KY (U S) 
Notice: Subject to any disclaimer, the term of this 
patent is extended or adjusted under 35 
USC 154(b) by 230 days. 
Appl. No.: 11/007,096 
Filed: Dec. 8, 2004 
Related US. Application Data 
Continuation of application No. 10/206,538, ?led on 
Jul. 26, 2002, noW abandoned. 
Provisional application No. 60/307,991, ?led on Jul. 
26, 2001, provisional application No. 60/308,450, 
?led on Jul. 27, 2001. 
Int. Cl. 
A01N 1/02 (2006.01) 
A01N 65/00 (2006.01) 
US. Cl. ...................................... .. 435/2; 424/93.72 
Field of Classi?cation Search ..................... .. None 
See application ?le for complete search history. 
(56) References Cited 
U.S. PATENT DOCUMENTS 
4,251,995 A * 2/1981 Pert etal. .................... .. 62/60 
4,469,227 A * 9/1984 Faust ........... .. 206/527 
5,795,711 A * 8/1998 Mullon et a1. 435/1.1 
5,863,715 A * 1/1999 Rajotte et a1. .............. .. 435/13 
* cited by examiner 
Primary ExamineriSandra E Saucier 
(74) Attorney, Agent, or FirmiKing & Schickli, PLLC 
(57) ABSTRACT 
Novel methods, compositions, and devices for achieving 
optimal cooling of living cells during cryopreservation are 
disclosed. In one aspect, the method comprises gradually 
cooling the cell to a ?rst predetermined temperature, followed 
by rapidly cooling the cell to a second predetermined tem 
perature. In another aspect, a device is described for achiev 
ing a desired cooling rate for a cell, comprising a ?rst con 
tainer for holding a cell, a second container for holding the 
?rst container, and optionally a frame for holding the ?rst 
container in a spaced apart relationship With the second con 
tainer. The method of the invention comprises placing cells 
into the ?rst container, placing the ?rst container in the second 
container and sealing the second container, and placing the 
second container in a suitable cooling device. In yet another 
aspect, novel cryoprotectant compositions are provided com 
prising conventional cryoprotectant plus one or more high 
molecular Weight cryoprotectants. 
8 Claims, 9 Drawing Sheets 
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METHODS AND DEVICES FOR 
CRYOPRESERVATION OF BIOLOGICAL 
CELLS AND TISSUES 
This application claims the bene?t of US. Provisional 
Patent Application Ser. Nos. 60/307,991, ?led on Jul. 26, 
2001 and 60/308,450, ?led on Jul. 27, 2001, both ofWhich are 
incorporated herein by reference, and is a continuation of 
US. patent application Ser. No. 10/206,538, ?led on Jul. 26, 
2002, noW abandoned the entirety of Which is also incorpo 
rated herein by reference. 
TECHNICAL FIELD 
The present invention relates to devices and methods for 
optimal cryopreservation of biological cells and tissues, and 
to cryoprotectant compositions. The invention further relates 
to devices and methods for accomplishing controlled cooling 
of various cell types during cryopreservation, maintaining 
optimal cooling rates according to speci?c cell types being 
cryopreserved. 
BACKGROUND OF THE INVENTION 
Cryopreservation of different cell types is critically in?u 
enced by cooling rate and cryoprotectant. Overly fast cooling 
rates can cause lethal intracellular formation of ice crystals. 
At the other end of the spectrum, overly sloW cooling rates can 
result in osmotic shock injury to cells. Further, conventional 
cryoprotectants, While essential to the successful freeZing of 
cells, are often toxic to the same cells in the thaWed state. 
Research has shoWn that for most biological cells, there is 
a speci?c cooling rate that may be considered optimal for the 
cell type. For example, for human hematopoietic progenitor 
cells (HPCs) the optimal cooling rates are knoWn to be from 
about 1° C./min. to about 3° C./min. Currently utiliZed com 
mercial devices for cooling cells for cryopreservation accom 
plish controlled temperature changes by injecting liquid 
nitrogen vapor through an electromagnetic valve. As the tem 
perature inside the devices increases or decreases, additional 
liquid nitrogen is inj ected to maintain the desired cooling rate. 
Disadvantageously, these cooling devices are expensive, 
require high rates of liquid nitrogen vapor consumption, and 
are unreliable due to the relative fragility of the required 
electromagnetic valves. Accordingly, there is a need in the art 
for inexpensive, reliable devices for maintaining narroWly 
tailored, optimal cooling rates for various cell types to be 
cryopreserved. 
It is desirable to maintain stores of a variety of cell types, 
some of Which may be relatively fragile cells, for future use. 
For example, platelets, particularly human platelets, are in 
Wide demand for a variety of uses requiring hemostasis such 
as standard transfusions in case of illness or trauma, chemo 
therapy, bone marroW transplants, and the like. The most 
common method for storage of platelets and certain other 
fragile cell types in, for example, blood banks, is so-called 
liquid storage, Whereinplatelets are maintained in liquid solu 
tions at room temperature for a maximum of 5 days, and 
discarded if not used. Attempting longer-ten storage of plate 
lets under such conditions results in progressive platelet aging 
and cytokine secretion, and risks microbial contamination. 
Further, screening processes for ensuring that donor platelets 
are immunologically compatible With prospective transfu 
sion candidates may require 3-5 days to complete, further 
shortening the WindoW of usefulness for stored platelets. 
Finally, there is currently no means for patients to store auto 
geneic platelets for long periods of time for future use. 
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Cryogenic preservation of cells is commonly employed 
When long-term storage of such cells is desirable. HoWever, at 
present there are no reliable cryopreservation techniques for 
fragile cell types such as platelets Which avoid the problems 
of loss of, eg viability, ability to secrete cytokines, and 
membrane stability. Accordingly, there is a need in the art for 
methods and devices for cryopreservation of cells, particu 
larly fragile cells such as platelets and hematopoietic stem 
cells, Which are reliable and do not result in cell damage and 
losses in viability. The present invention satis?es this need in 
the art by providing a method for cryopreservation of cells. 
The invention further provides devices suitable for cryo 
preservation of cells, including fragile cells, in accordance 
With the methods described. 
SUMMARY OF THE INVENTION 
In accordance With the purposes of the present invention as 
described herein, in one aspect of the present invention a 
method for cryopreservation of a living cell, particularly a 
fragile cell type, is provided, comprising placing the cell in a 
cryoprotectant having a cryoprotectant agent, gradually cool 
ing the living cell in cryoprotectant to a ?rst predetermined 
temperature, and rapidly cooling the living cell in cryopro 
tectant from the ?rst predetermined temperature to a second 
predetermined temperature. The step of gradually cooling the 
cell may include cooling at a rate of betWeen about 1° 
C./minute and about 3° C./minute. The ?rst predetermined 
temperature may be betWeen about —30° C. and about —40° C. 
Typically, the ?rst predetermined temperature is about —30° 
C. The second predetermined temperature may be betWeen 
about —80° C. and about —196° C. The rapid cooling step may 
be accomplished by immersing the cells and cryoprotectant in 
liquid nitrogen. Suitable cryoprotectants may be selected 
from a group consisting of dimethyl sulfoxide, polyvinylpyr 
rolidine, polyethylene glycol and mixtures thereof. The 
method of the invention is particularly suited for cryopreser 
vation of a fragile cell type, for example a platelet or a 
hematopoietic stem cell. 
In another aspect, a method for cryopreservation of a living 
cell is provided, comprising placing the living cell in a cryo 
protectant including a cryoprotectant agent into a ?rst con 
tainer and sealing the ?rst container. The ?rst container 
including the living cell and cryoprotectant may then be 
placed into a second container, and the second container 
sealed. An insulating space is preserved betWeen the ?rst and 
second containers by any suitable means, such as by placing 
the ?rst container in a rack prior to insertion into the second 
container. 
The next step is gradually cooling the living cell in cryo 
protectant at a rate of about 1° C./minute to about 3° 
C./minute to a desired temperature, typically —80° C. For 
longer term storage, the living cell may then be rapidly cooled 
to a second predetermined temperature, such as by immersing 
in liquid nitrogen. 
The ?rst and second containers may be constructed of any 
suitable material. Typically, the ?rst container Will be con 
structed of aluminum. The second container Will typically be 
constructed of stainless steel. HoWever, as Will be described 
in greater detail beloW, it Will be appreciated that the materials 
of Which the ?rst and second containers are constructed may 
be varied in accordance With the desired heat transfer prop 
erties to achieve a speci?c, predetermined cooling rate. 
In yet another aspect, the present invention provides an 
apparatus for accomplishing the aforesaid method and hold 
ing living cells for cooling during cryopreservation, compris 
ing a ?rst container for receiving and holding the living cells 
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and a second container for receiving and holding the ?rst 
container. The second container may be sealed around the 
?rst container to de?ne a space betWeen the exterior Wall of 
the ?rst container and the interior Wall of the second con 
tainer. Typically, this space Will be air-?lled. However, it Will 
be appreciated that other materials having greater or lesser 
insulating properties may be used in accordance With the 
desired cooling rate achievable With the device. Typically, the 
?rst container may be constructed from aluminum and the 
second container may be constructed from stainless steel. 
HoWever, the materials of Which the ?rst and second contain 
ers are constructed may be varied in accordance With the 
desired heat transfer properties to achieve a speci?c, prede 
termined cooling rate. For example, if a faster cooling rate is 
desired, a second container constructed entirely or partially 
from copper may be used. 
In still yet another aspect of the present invention, a novel 
cryoprotectant composition for cryopreservation of a cell is 
provided, comprising conventional cryoprotectant agents in 
combination With high molecular Weight cryoprotectant 
agents. The cryoprotectant agents may be selected from the 
group consisting of dimethyl sulfoxide, polyvinylpyrrolidine, 
polyethylene glycol, and any mixture thereof. Typically, the 
cryoprotectant of the present invention comprises dimethyl 
sulfoxide mixed With polyvinylpyrrolidine, polyethylene 
glycol, or mixtures of polyvinylpyrrolidine and polyethylene 
glycol. In one embodiment, the cryoprotectant may include 
about 0.5 to about 1.0 M dimethyl sulfoxide mixedWith about 
5.0 to about 15% (W/v) polyvinylpyrrolidine, typically 10%. 
In another embodiment, the cryoprotectant may include 
about 0.5 to about 1.0 M dimethyl sulfoxide mixedWith about 
0.1 to about 4% (W/v) polyethylene glycol, typically 2.0%. 
Other objects and applications of the present invention Will 
become apparent to those skilled in this art from the folloWing 
description Wherein there is shoWn and described a preferred 
embodiment of this invention, simply by Way of illustration of 
the modes currently best suited to carry out the invention. As 
it Will be realiZed, the invention is capable of other different 
embodiments and its several details are capable of modi?ca 
tion in various, obvious aspects all Without departing from the 
invention. Accordingly, the draWings and descriptions Will be 
regarded as illustrative in nature and not as restrictive. 
BRIEF DESCRIPTION OF THE DRAWING 
The accompanying draWing incorporated in and forming a 
part of the speci?cation illustrates several aspects of the 
present invention and, together With the description, serves to 
explain the principles of the invention. In the draWing: 
FIG. 1 shoWs aggregation of platelets folloWing freeZing to 
different temperatures, With or Without immersion in liquid 
nitrogen. The cryoprotectant used Was 1 M DMSO. 
FIG. 2 shoWs release of LDH by platelets folloWing freeZ 
ing to different temperatures, With or Without immersion in 
liquid nitrogen. 
FIG. 3 is a schematic representation of the device for cool 
ing a cell at a desired rate. 
FIGS. 4a and 4b shoW calculated temperature histories of 
PBS/DMSO mixtures contained Within the device of FIG. 3; 
(a) calculated temperature Within sample as a function of 
varying second container Wall thickness; (b) calculated tem 
perature Within sample as a function of varying freeZer tem 
perature 
FIG. 5 shoWs the predicted temperature histories Within 
sample bags (In) and at a Wall of the second container of the 
device of this invention (Out) compared to calculated histo 
r1es. 
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FIG. 6 shoWs platelet aggregation in the presence of vary 
ing compositions of cryoprotectant agent after freeZing and 
thaWing to various temperatures. 
FIG. 7 shoWs platelet LDH release in the presence of vary 
ing compositions of cryoprotectant agent after freeZing and 
thaWing to various temperatures. 
FIG. 8 shoWs platelet LDH release in the presence of vary 
ing combinations of DMSO and polyvinylpyrrolidine. 
>X‘:P<0.01, #:P<0.05 compared to the —20 C group; 
+:P<0.05 compared to the —40 C group. 
FIG. 9 shoWs platelet activation, measured as binding of 
Annexin V by How cytometry, after freeZing and thaWing. 
FIG. 10 shoWs platelet aggregation as a function of storage 
of cells in liquid nitrogen over time. 
Reference Will noW be made in detail to the presently 
preferred embodiments of the invention, examples of Which 
are illustrated in the accompanying draWing. 
DETAILED DESCRIPTION OF THE INVENTION 
In one aspect, the present invention provides a method for 
cryopreservation of various fragile cell types, including a 
graduated cooling rate method Wherein cells are cooled to a 
desired ?rst predetermined temperature, then placed directly 
into a commonly used freeZing medium such as liquid nitro 
gen. In another aspect, the present invention provides a com 
bination of cryoprotectants Which optimiZe freeZing of fragile 
cell types While minimiZing the knoWn cytotoxic effects of 
certain cryoprotectants on thaWed cell preparations. 
Example 1 
Human platelet concentrates (up to 1 day in age) Were 
obtained and kept at 22 C With continuous agitation in modi 
?ed Tyrode’s buffer solution and mixed (1 :1) With 1 M dim 
ethyl sulfoxide (DMSO) as cryoprotectant. Paired aliquots of 
platelet concentrates in vials Were cooled in a BioCool system 
(BCIV40, Stone Ridge, NY.) at a cooling rate of 1 C/min. to 
—5, —15,—20, —25, —30, —35, and —400 C. At —50 C., a metal 
probe precooled in liquid nitrogen Was used to induce ice 
seeding in the vials in a manner knoWn in the art to prevent 
uncontrolled formation of ice crystals, and cooling Was con 
tinued. Upon reaching the predetermined temperature as 
noted supra, one aliquot of platelet concentrate Was trans 
ferred directly to liquid nitrogen (temperature —196 C), While 
the other aliquot of the pair Was thaWed in a 37 C Water bath 
in accordance With standard methodology for thaWing cryo 
preserved cells. After 10 minutes to alloW the liquid nitrogen 
boiling phenomenon to dissipate, the second paired aliquot of 
platelet concentrate Was similarly thaWed at 37 C. After thaW 
ing, platelet function Was evaluated as noted infra. 
Following freeZing and thaWing experiments as noted 
above, platelets Were evaluated for complete counts by 
microscopy and particle counter (Coulter Counter, Z M, 
Luton, England), for release of lactate dehydrogenase (LDH) 
by spectrophotometry using a kit in accordance With the 
manufacturers directions (Sigma, St. Louis, Mo.), and for 
platelet aggregation by aggregometer in accordance With the 
manufacturers directions (PACKS-4, platelet aggregation 
chromogenic system, Helena Laboratories, Beaumont, Tex.) 
in response to the agonists propyl gallate (0.03 mM), ADP (20 
uM), epinephrine (300 uM), ristocetin (1.5 mg/ml), and col 
lagen (10 ug/ml). 
Fresh human platelet sample counts Were 1.83-2.89><109/ 
ml. After freeZe-thaWing, cell numbers declined slightly 
(1 .67-2.62><109/ml), or slightly better than 90% recovery 
(90.05%:275) (n:10, P>0.05). 
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Cooling of platelet concentrate in l M. DMSO resulted in 
decreased percent platelet aggregation and increased LDH 
release. As seen in FIGS. 1 and 2, the freeZe-thaWing experi 
ments shoWed that the intracellular ice formation point Was 
betWeen —30 C and —35 C. 
In another aspect of the present invention, a method and 
device for achieving an optimal cooling rate during cryo 
preservation in accordance With the needs of a particular cell 
type is described. The device is robust, reliable, and signi? 
cantly less expensive than currently employed devices for 
cooling cells during cryopreservation. As best visualiZed 
schematically in FIG. 3, the cooling system 10 of the present 
invention comprises a ?rst container 20 for holding cells or a 
bag holding a suspension of cells, a second container 22 into 
Which one or more ?rst containers 20 may be placed, and a 
cover (not shoWn for convenience) for sealing the second 
container 22 With the ?rst container 20 therein. A frame (not 
shoWn for purposes of convenience) capable of slidably 
receiving the ?rst container 20 may also be provided to 
increase ease of handling of multiple ?rst containers 20. As 
shoWn schematically in FIG. 5, the frame also maintains the 
?rst container 20 and second container 22 in a spaced-apart 
relationship, providing a space 24 therebetWeen. Typically, 
space 24 Will be air-?lled. HoWever, it should be appreciated 
that any suitable insulating material may be used to ?ll space 
24, for example When a sloWer cooling rate is desired Withuse 
the cooling system 10 of the present invention. Heat exchange 
betWeen air and chamber Wall is caused by natural convec 
tion. Heat ?ux ?oWs vertically through the chamber Wall 
along the direction indicated by arroW A. 
Example 2 
In accordance With the methods of the invention, living 
cells at room temperature are placed in a standard blood bag 
With cryoprotectant (600 ml of cell suspension in a ?nal 
concentration of 10% DMSO in buffer). The blood bags are 
then placed in a ?rst, aluminum container. One or more ?rst 
aluminum containers are then inserted into a metal frame and 
the frame is inserted into a second container and covered. In 
a presently preferred embodiment, the second container is 
constructed of stainless steel. The second, stainless steel con 
tainer is then placed into a suitable cooling device, typically a 
—80° C. freeZer of knoWn design. In this fashion, a controlled 
cooling rate is achieved, alloWing cryopreservation of cells 
Without fear of damage from ice crystal formation or osmotic 
shock injury. 
Example 3 
The effects of varying parameters of the method and device 
of the present invention Were evaluated. The parameters 
evaluated were: (1) concentration of cryoprotectant [dimethyl 
sulfoxide (DMSO)]; (2) Wall thickness of the second, stain 
less steel bag; (3) sample mass/volume; and (4) surrounding 
temperature to Which the device of the invention is exposed. 
Sixty ml samples of phosphate-buffered saline (PBS) con 
taining varying concentrations of DMSO Were placed in 
blood bags of a type knoWn in the art. The blood bags con 
taining PBS/DMSO Were placed into the device of the instant 
invention as described in Example 2, and the entire device of 
the instant invention Was then placed in a freeZer at —80° C. 
Temperature histories at different locations Within the ?rst, 
aluminum bag, the second, stainless steel bag, and the blood 
bag containing PBS/DMSO Were recorded using thermo 
couples. The experiment continued until the temperature in 
all samples reached —80° C. 
As seen in FIG. 4a, varying the Wall thickness of the 
second, stainless steel bag alloWed varying the cooling rate. 
The rate of cooling Was inversely proportional to the thick 
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ness of the Wall, i.e. the thinner the Wall, the more rapid the 
rate of cooling. Similarly, the cooling rate increased greatly 
With the decreasing temperature Within the freeZer (FIG. 4b). 
Sample siZe and concentration of cryoprotectant did not sig 
ni?cantly affect cooling rate. It Will therefore be appreciated 
that it is possible to vary the rate of cooling to a desired rate by 
varying the Wall thickness of the second container 22 and/or 
the temperature at Which the freeZer is set, alloWing estab 
lishment of a predetermined rate of cooling in accordance 
With the speci?c requirements of the cells being cryopre 
served. Thus, the present invention also provides a method of 
optimiZing cooling conditions, i.e. the cooling rate of cells 
being cryopreserved, according to the speci?c needs of the 
cell type of interest. 
Based on heat transfer principles, the chamber Wall With a 
convective heat transfer boundary condition may be consid 
ered as a unit Whose interior temperatures are nearly uniform 
if the folloWing condition is satis?ed 
an 
Biot's nurnberB" K <01 
Where h is the convective heat transfer coef?cient of the ?uid, 
kW is the thermal conductivity of stainless steel, and L is the 
speci?ed length of the second container Wall. The above 
equation indicates that to ensure that the thermal properties of 
the device of the present invention, internal conductive resis 
tance should be much smaller than its external convective 
resistance. The mathematical formulation of an Energy con 
servation equation of the second container Wall can be shoWn 
as beloW 
out’ st 
Where E01” is the heat loss of the second container Wall, and 
Est is the internal energy change of chamber Wall. 
Accordingly, 
(1) 
TAO) = To 
Where mW is the mass of the second container Wall, cW is the 
speci?c heat of stainless steel, T0(t) represents the tempera 
ture of the second container Wall at different times, t repre 
sents the time, q is the net heat ?ux into chamber Wall, AS is the 
surface area of chamber Wall, TS is the surrounding tempera 
ture, ql is the heat ?ux from the aluminum ?rst container into 
the second container Wall, and T0 is the temperature at initia 
tion of freeZing. 
The convective heat exchange coe?icient can be calculated 
as 
Kl 
h 
Ral 
Where Ral is Raleigh’ s number, F(Ral) is the empirical func 
tion of outside surface convection, g is the gravity accelera 
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tion, [3 is the ratio of air volume expansion to temperature, v 
is the dynamic viscosity of air, and 0t is the thermal diffusivity 
of air. 
In accordance With the method of this invention, a ?rst 
aluminum container containing living cells in cryoprotectant 
is placed inside the second, stainless steel container. The ?rst 
container/ cells exchange heat With the second container Wall 
through an air layer betWeen the ?rst container and the second 
container Wall. The conductive resistance of the air layer is 
much larger than the ?rst container’s internal conductive 
resistance. Accordingly, the heat transfer properties of the 
?rst canister and the cell samples may be combined in the 
calculations. The model may be expressed as: 
WmSCSZ-(U) : (2) 
Ti(0) = To 
Where T,(t) is the temperature inside the ?rst container, RC0” 
is the thermal resistance of the air layer, and mScS is the heat 
capacity of the cell samples inside the ?rst container. Accord 
ingly: 
mscsImaca+mpcp+rnccc+rnncn+rnhc,l 
Where macq, mpcp, mccb, mncwmhmh are the heat capacities 
of the aluminum camster, freeZ1ng bag, CPA, salt and Water 
respectively. 
From Kirchoff s Equation: 
[aLf 
Where Cpl and Cps are the speci?c heats of liquid Water and 
ice respectively, f(T2) is the fraction of ice, L/(TZ) is the latent 
heat of Water solidi?cation at T2 and LfO is the latent heat of 
Water solidi?cation at 0° C. 
The froZen fraction of Water, f(T2) in the Water-NaCl 
DMSO solution during freeZing process can be derived from 
the analytical equations describing the phase diagrams of the 
ternary solution: 
Where W(T2) is the solution of the equation shoWn beloW: 
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-continued 
arclg(R/2) 
B _ T— 0.001 
C = —4.5 X 10’4 
Where WD, WN and WHO are the initial mass fractions of 
Me2SO, salt and Water in Water-NaCl-Me2SO solution 
respectively, and W(T2) the solute mass fraction in solution at 
T2. 
In a Water-NaCl-glycerol ternary system, the fraction of 
froZen Water f(T2) may be expressed as: 
Where WG is the glycerol mass fraction of the solution. 
Equations (1) and (2) Were discretiZed and calculated 
coupledly stepWise in response to time step interval. The 
folloWing conditions Were assumed in the calculation: 
(1) Time step interval: 0.1 second 
(2) Initial sample temperature: T(0):22o C. 
(3) solution supercooling temperature is 00 C. (this is derived 
from experimental results) 
(4) Thermophysical properties of the materials used in the 
calculation change With the temperature change. 
According to these conditions, Biot’s number Was esti 
mated as 
. M (3) 
Bl : F 2: 0.00059<< 0.1 
1 
and the ratio of the internal thermal resistance of the ?rst 
container to the air layer betWeen the ?rst container and the 
second container Wall (r. /r )was In air 
Formulas (3) and (4) indicate that the thermal properties of 
the second container Wall and the ?rst container may be 
combined according to the conditions used in this calculation. 
Effects of four factors on the sample temperature history in 
Water-NaCl-DMSO Were calculated: 
(1) DMSO concentration 
(2) Thickness of stainless steel bag Wall 
(3) HPCs sample mass/volume 
(4) Surrounding temperature inside the freeZer 
It Will therefore be appreciated that, using the calculations 
as described above, it is possible using knoWn thermal trans 
fer properties of any material to design devices in accordance 
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With the present invention Which maintain a speci?c, optimal 
cooling rate for a particular cell type. Optimal cooling rates 
for any cell type may be obtained from the literature, or may 
be determined experimentally by knoWn methods. Accord 
ingly, in yet another aspect of the present invention, a soft 
Ware program alloWing selection of speci?c elements of the 
present invention as described above is provided to tailor the 
device of the invention to the speci?c cooling rate require 
ments of particular cell types. The software predicts an opti 
mal cooling rate for a particular ?uid system using knoWn 
heat transfer principles and mathematical formulae as 
described above incorporating heat transfer properties of: (1) 
the ?rst container; (2) the ?uid(s) (With cells) contained in the 
?rst container; (3) the second container: (4) the air betWeen 
the ?rst and second containers; and (5) the dimensions of the 
second container. The softWare program of the present inven 
tion alloWs prediction of cooling rates in accordance With the 
above factors, and therefore is able to predict the cooling rate 
achievable With the device of the instant invention as 
described supra regardless of the dimensions of the device, 
materials used to construct the device, and the like. 
Example 4 
A device for cooling a cell Was constructed as described 
above, comprising an aluminum ?rst container 20, a stainless 
steel second container 22, a frame for holding ?rst container 
20 inside second container 22, and a cover for second con 
tainer 22. Conventional blood bags containing PBS plus 10% 
DMSO Were placed in ?rst containers 20, the ?rst containers 
20 Were placed in the second container 22 and into a —80° C. 
freezer. The second container 22 had a Wall thickness of 0.03 
inches. Temperatures at varying locations Within the device 
Were recorded using thermocouples as described in Example 
3. Predicted temperatures Were obtained using the softWare 
program of the present invention. As shoWn in FIG. 5, the 
softWare program of the present invention accurately pre 
dicted temperature histories for the PBS/DMSO samples, as 
Well as for the second container Wall. 
It Will therefore be appreciated that this softWare program 
alloWs the user to design a device in accordance With the 
method of the instant invention of speci?c dimensions, mate 
rials, etc. to achieve a cooling rate optimal for the particular 
cell type to be cryopreserved. For example, a copper second 
container could be used to achieve a more rapid cooling rate. 
An insulating material, such as styrofoam or any other insu 
lating polymer, could be used to ?ll the airspace betWeen the 
?rst and second containers to reduce the cooling rate. Regard 
less, upon input of the proper parameters as described above, 
the proper device may be designed using the softWare of this 
invention to achieve the desired cooling rate. 
Accordingly, the method and device of the present inven 
tion provides a reliable, effective means for achieving a 
desired cooling rate during cryopreservation, minimiZing the 
risk of damage to cells from osmotic shock injury or intrac 
ellular ice crystal formation. The method is suitable for cryo 
preservation of any cell type, including fragile cells such as 
bone marroW/cord blood hematopoietic progenitor cells for 
cancer treatment and gene therapy, for tissue cryopreserva 
tion for transplantation, for spem1/ oocyte preservation for 
arti?cial insemination and in vitro fertilization, for cryo 
preservation of cell lines for research, and the like. 
In still yet another aspect of the present invention, a novel 
cryoprotectant composition for cryopreservation of a cell is 
provided, comprising conventional cryoprotectant agents in 
combination With high molecular Weight cryoprotectant 
agents. The cryoprotectant agents may be selected from the 
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group consisting of dimethyl sulfoxide, polyvinylpyrrolidine, 
polyethylene glycol, and any mixture thereof. Typically, the 
cryoprotectant of the present invention comprises dimethyl 
sulfoxide mixed With polyvinylpyrrolidine, polyethylene 
glycol, or mixtures of polyvinylpyrrolidine and polyethylene 
glycol. 
Example 5 
Human platelet concentrates (up to 1 day in age) Were 
obtained and kept at 22 C With continuous agitation in modi 
?ed Tyrode’s buffer solution and mixed (1:1) With various 
cryoprotectant solutions. The novel cryoprotectant solutions 
comprise standard dimethyl sulfoxide (DMSO) plus large 
molecular Weight cryoprotectants. The cryoprotectant solu 
tions evaluated included dimethyl sulfoxide (DMSO), poly 
vinylpyrrolidone (PVP), polythyleneglycol (PEG), and mix 
tures thereof. DMSO Was utiliZed as the basic cryoprotectant, 
and evaluated at 0 M, 0.25 M, 0.5 M, and 1.0 M (?nal con 
centration). A cryoprotectant mixture comprising DMSO and 
PVP at 0%, 2.5%, 5.0%, 7.5%, and 10% (W/v) Was evaluated 
to determine the optimal cryoprotectant mixture for this cell 
type. A cryoprotectant mixture comprising DMSO and PEG 
at 2%, 5%, 7.5%, and 10% (W/v) Was evaluated also. For 
evaluation of cytotoxicity, platelet concentrates Were mixed 
With cryoprotectants as noted above (1:1 ratio) and main 
tained at room temperature for tWo hours. Platelet function 
Was then evaluated as noted infra. Graduated cooling experi 
ments Were conducted as described in Example 1, and platelet 
function tests as described above Were conducted. 
Addition of high molecular Weight cryoprotectants to stan 
dard cryoprotective solutions (DMSO) improved functional 
ity and membrane stability of cryopreserved platelets in com 
parison to DMSO alone. In particular, solutions comprising 
DMSO and 2.5% and 5% PVP improved platelet aggregation 
and reduced LDH release folloWing cryopreservation (FIGS. 
6 and 7). Similarly, cryopreservation solutions comprising 
0.5 and 1 M DMSO and 10% PVP reduced LDH release (FIG. 
8). Cryopreservation solutions comprising 0.5 M DMSO and 
2% PEG gave good results in platelet aggregation tests fol 
loWing freeZing, but tended to exhibit increased LDH release 
from platelets (not shoWn). 
Addition of higher molecular Weight cryoprotectants also 
reduced activation of platelets folloWing freeZing and thaW 
ing, determined as binding of Annexin V as measured by 
standard ?oW cytometric techniques for assessing binding of 
various antibodies (Gao et al., 1999. Cryobiology, 38: 225 
235, incorporated herein by reference). In particular, a cryo 
protective solution comprising 0.5 M DMSO and 10% PVP 
(W/v) Was particularly effective (FIG. 9). 
In separate experiments, effects of inclusion of large 
molecular Weight cryoprotectants (0.5 M DMSO plus 10% 
polyvinylpyrrolidine) on long-term storage of platelets Was 
evaluated. Platelet concentrates Were cooled as described in 
Example 1 and transferred to liquid nitrogen for storage. As 
noted in FIG. 10, post-thaW platelet aggregation folloWing 
froZen storage for 12 and for 18 days Was essentially 
unchanged. 
Accordingly, the methods and composition of the instant 
invention, comprising inclusion of large molecular Weight 
cryoprotectants to standard cryoprotection solutions, have 
been found to be useful in preservation of membrane stability 
of fragile cell types such as platelets folloWing freeZe-thaW 
ing. The method is suitable for long-term cryopreservation of 
fragile cells such as platelets, and advantageously alloWs 
banking of such cells for future requirements. It Will be appre 
ciated that the methods and compositions of the present 
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invention further have utility for bone marroW/cord blood 
hematopoietic progenitor cells for cancer treatment and gene 
therapy, for tissue cryopreservation for transplantation, for 
sper'm/oocyte preservation for arti?cial insemination and in 
vitro fertilization, for cryopreservation of cell lines for 
research, and the like. 
The foregoing description of a preferred embodiment of 
the invention has been presented for purposes of illustration 
and description. It is not intended to be exhaustive or to limit 
the invention to the precise form disclosed. Obvious modi? 
cations or variations are possible in light of the above teach 
ings. The embodiment Was chosen and described to provide 
the best illustration of the principles of the invention and its 
practical application to thereby enable one of ordinary skill in 
the art to utiliZe the invention in various embodiments and 
With various modi?cations as are suited to the particular use 
contemplated. All such modi?cations and variations are 
Within the scope of the invention as determined by the 
appended claims When interpreted in accordance With the 
breadth to Which they are fairly, legally and equitably entitled. 
What is claimed is: 
1. A method for cryopreservation of a cell, comprising: 
placing a cell in a bag including a cryoprotectant agent and 
placing the bag into a ?rst container; 
placing the ?rst container into a second container Whereby 
an insulating space is de?ned betWeen the ?rst container 
and the second container; 
sealing the second container; 
gradually cooling the cell in cryoprotectant at a ?rst cool 
ing rate of from about 10 C./minute to about 3° 
C./minute by placing the bag in a ?rst cooling device 
providing a ?rst surrounding temperature of betWeen 
about —60° C. to about —80° C. until a ?rst temperature 
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of the cell and cryoprotectant agent of betWeen about 
—30° C. to about —80° C. is reached; 
Wherein the ?rst cooling rate is optimiZed for the cell type 
and controlled by the Wall thickness of the second con 
tainer and/ or insulative properties of the ?rst and/ or sec 
ond container; and 
transferring the sealed second container to a second cool 
ing device providing a second surrounding temperature 
Which is loWer than the ?rst surrounding temperature 
and is betWeen about —80° C. to about —196° C.; 
Whereby the cell placed in the ?rst container is cryopre 
served. 
2. The method of claim 1, Wherein the ?rst container is 
fabricated of aluminum. 
3. The method of claim 1, Wherein the second container is 
fabricated of stainless steel. 
4. The method of claim 1, Wherein the cell is a platelet. 
5. The method of claim 1, Wherein the cryoprotectant is 
selected from a group consisting of dimethyl sulfoxide, poly 
vinylpyrrolidine, polyethylene glycol, and any mixture 
thereof. 
6. The method of claim 1, Wherein the ?rst temperature of 
the cell and cryoprotectant agent is betWeen about —30° C. to 
about —400 C. 
7. The method of claim 5, Wherein the cryoprotectant con 
sists essentially of from about 0.5 M to about 1.0 M dimethyl 
sulfoxide and from about 5.0% (W/v) to about 15% (W/v) 
polyvinylpyrrolidine. 
8. The method of claim 5, Wherein the cryoprotectant con 
sists essentially of from about 0.5 M to about 1.0 M dimethyl 
sulfoxide and from about 0.1% (W/v) to about 4.0% (W/v) 
polyethylene glycol. 
